filings.toolsItem 16. Form 10-K Summary
5K characters. Original on sec.gov · Markdown
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AGILENT TECHNOLOGIES, INC. | ||||||||||||||
| BY | /s/ PADRAIG MCDONNELL | |||||||||||||
| Padraig McDonnell | ||||||||||||||
| President and Chief Executive Officer | ||||||||||||||
Date: December 19, 2024
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Bret DiMarco and P. Diana Chiu, or either of them, his or her attorneys-in-fact, for such person in any and all capacities, to sign any amendments to this report and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that any of said attorneys-in-fact, or substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date | ||||||||||||
| /s/ PADRAIG MCDONNELL | Director, President and Chief Executive Officer | December 19, 2024 | ||||||||||||
| Padraig McDonnell | (Principal Executive Officer) | |||||||||||||
| /s/ ROBERT W. MCMAHON | Senior Vice President and Chief Financial Officer | December 19, 2024 | ||||||||||||
| Robert W. McMahon | (Principal Financial Officer) | |||||||||||||
| /s/ RODNEY GONSALVES | Vice President, Corporate Controllership | December 19, 2024 | ||||||||||||
| Rodney Gonsalves | (Principal Accounting Officer) | |||||||||||||
| /s/ KOH BOON HWEE | Chairman of the Board of Directors | December 19, 2024 | ||||||||||||
| Koh Boon Hwee | ||||||||||||||
| /s/ MALA ANAND | Director | December 19, 2024 | ||||||||||||
| Mala Anand | ||||||||||||||
| /s/ OTIS W. BRAWLEY, M.D. | Director | December 19, 2024 | ||||||||||||
| Otis W. Brawley, M.D. | ||||||||||||||
| /s/ G. MIKAEL DOLSTEN, M.D., PH.D. | Director | December 19, 2024 | ||||||||||||
| G. Mikael Dolsten, M.D., PH.D. | ||||||||||||||
| /s/ HEIDI KUNZ | Director | December 19, 2024 | ||||||||||||
| Heidi Kunz | ||||||||||||||
| /s/ DANIEL K. PODOLSKY, M.D. | Director | December 19, 2024 | ||||||||||||
| Daniel K. Podolsky, M.D. | ||||||||||||||
| /s/ SUE H. RATAJ | Director | December 19, 2024 | ||||||||||||
| Sue H. Rataj | ||||||||||||||
| /s/ GEORGE A. SCANGOS, Ph.D. | Director | December 19, 2024 | ||||||||||||
| George A. Scangos, Ph.D. | ||||||||||||||
| /s/ DOW R. WILSON | Director | December 19, 2024 | ||||||||||||
| Dow R. Wilson |
Previous: Item 15. Exhibits and Financial Statement Schedules